BACKGROUND AND OBJECTIVES: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective cohort with biopsy-proven IgAN in Calgary, Canada. Renal biopsies were reviewed by a nephropathologist with histopathologic data abstracted using a standardized form. The primary outcome was the composite of doubling of serum creatinine, ESRD, or death. Spline models defined significant levels of interstitial fibrosis, glomerulosclerosis, hypertension, proteinuria, and creatinine. The prognostic significances of clinical and histopathologic parameters were determined using Cox proportional hazards models. RESULTS: Data from 146 cases were available for analysis with a median follow-up of 5.8 years. Greater than 25% interstitial fibrosis, >40% glomerular sclerosis, and a systolic BP >150 mmHg were risk thresholds. In univariable analyses, baseline creatinine, proteinuria, systolic BP, glomerular sclerosis, interstitial fibrosis, and crescentic disease were predictors of the primary outcome. In multivariable models adjusted for clinical characteristics, interstitial fibrosis (hazard ratio [HR]2.7; 95% confidence interval [CI] 1.2 to 6.0), glomerular sclerosis (HR 2.6; 95% CI 1.2 to 4.5), and crescents (HR 2.4; 95% CI 1.2 to 5.1) remained independent predictors of the primary outcome and significantly improved model fit compared with clinical characteristics alone. CONCLUSIONS: Baseline histopathologic parameters are independent predictors of adverse outcomes in IgAN even after taking into consideration clinical characteristics. Relatively small degrees of interstitial fibrosis confer an increased risk for progressive IgAN.
BACKGROUND AND OBJECTIVES:IgAnephropathy (IgAN) is the most common primary glomerular disease worldwide. Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective cohort with biopsy-proven IgAN in Calgary, Canada. Renal biopsies were reviewed by a nephropathologist with histopathologic data abstracted using a standardized form. The primary outcome was the composite of doubling of serum creatinine, ESRD, or death. Spline models defined significant levels of interstitial fibrosis, glomerulosclerosis, hypertension, proteinuria, and creatinine. The prognostic significances of clinical and histopathologic parameters were determined using Cox proportional hazards models. RESULTS: Data from 146 cases were available for analysis with a median follow-up of 5.8 years. Greater than 25% interstitial fibrosis, >40% glomerular sclerosis, and a systolic BP >150 mmHg were risk thresholds. In univariable analyses, baseline creatinine, proteinuria, systolic BP, glomerular sclerosis, interstitial fibrosis, and crescentic disease were predictors of the primary outcome. In multivariable models adjusted for clinical characteristics, interstitial fibrosis (hazard ratio [HR]2.7; 95% confidence interval [CI] 1.2 to 6.0), glomerular sclerosis (HR 2.6; 95% CI 1.2 to 4.5), and crescents (HR 2.4; 95% CI 1.2 to 5.1) remained independent predictors of the primary outcome and significantly improved model fit compared with clinical characteristics alone. CONCLUSIONS: Baseline histopathologic parameters are independent predictors of adverse outcomes in IgAN even after taking into consideration clinical characteristics. Relatively small degrees of interstitial fibrosis confer an increased risk for progressive IgAN.
Authors: Fernand Mac-Moune Lai; Cheuk Chun Szeto; Paul Cheung Lung Choi; Philip Kam Tao Li; Nelson Leung Sang Tang; Kai Ming Chow; Siu Fai Lui; Teresa Yuk Hwa Wong; Kelvin K L Ho; Ka Fai To Journal: Am J Kidney Dis Date: 2002-02 Impact factor: 8.860
Authors: G D'Amico; L Minetti; C Ponticelli; G Fellin; F Ferrario; G Barbiano di Belgioioso; E Imbasciati; A Ragni; S Bertoli; G Fogazzi Journal: Q J Med Date: 1986-04
Authors: Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang Journal: Kidney Int Date: 2009-07-01 Impact factor: 10.612
Authors: Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts Journal: J Nephrol Date: 2015-08-30 Impact factor: 3.902
Authors: Hanni Menn-Josephy; Carol S Lee; Angela Nolin; Marta Christov; Denis V Rybin; Janice M Weinberg; Joel Henderson; Ramon Bonegio; Andrea Havasi Journal: Am J Nephrol Date: 2016-09-15 Impact factor: 3.754
Authors: Mark Haas; Jacobien C Verhave; Zhi-Hong Liu; Charles E Alpers; Jonathan Barratt; Jan U Becker; Daniel Cattran; H Terence Cook; Rosanna Coppo; John Feehally; Antonello Pani; Agnieszka Perkowska-Ptasinska; Ian S D Roberts; Maria Fernanda Soares; Hernan Trimarchi; Suxia Wang; Yukio Yuzawa; Hong Zhang; Stéphan Troyanov; Ritsuko Katafuchi Journal: J Am Soc Nephrol Date: 2016-09-09 Impact factor: 10.121